Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
Michael Mina, MD, PhD
Advertisement
Michael Mina, MD, PhD, is the CMO and chief epidemiologist at Invivyd.
Articles by Michael Mina, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
2
Postvaccine Hepatitis Reports More Often Serious in Children vs Adults
3
CMS Moves TIC Reporting to Quarterly, Sets Drug File Timeline
4
Up to 400 mg of Caffeine Daily Is Safe for Most Adults, AHA Says
5